News & Events
2024-05-27
Syncell Holds Grand Opening of Headquarters Office in Taipei Bioinnovation Park

(Photo caption: From left to right: Vice President of Diamond Biofund Inc Yen Chen Huang, Project Director of Strategic Investment of Hermes-Epitek Corporation Pozo Weng, Syncell Founder and CEO Jung-Chi Liao, Institute for Biotechnology and Medicine Industry (IBMI) Vice President and Academician of Academia Sinica Dr. Pan-Chyr Yang, Director of Taya Venture Dalon Wu, Founding Partner of Darwin Venture Management Simon Fang)


Following the opening of Syncell's Boston office on April 26, the company held a grand opening ceremony for its headquarters in the Taipei Bioinnovation Park on the 27th. Distinguished guests included Dr. Pan-Chyr Yang, Academician of Academia Sinica and Vice President of the Institute for Biotechnology and Medicine Industry, who offered his congratulations. Key investors in Syncell, such as Diamond Biofund Inc., Hermes-Epitek Corporation, Taya Venture, and Darwin Venture Management, attended the ribbon-cutting ceremony.

In his speech, Dr. Pan-Chyr Yang expressed his anticipation for Syncell's future development, stating that the company's technology will bring significant changes to the biomedical field.

Jung-Chi Liao, founder and CEO of Syncell, noted that despite being established only four years ago, Syncell has already completed product development and manufacturing, successfully installing machines at customer sites in the United States. To date, Syncell’s core technology has been effectively applied in identifying previously unknown protein components related to diseases such as triple-negative breast cancer, Alzheimer's disease, amyotrophic lateral sclerosis, and fatty liver disease.

Syncell has been invited to participate in prestigious international conferences, including the 2024 Cacib-APSOT Asia Pacific Spatial Omics Technology Conference and the American Association for Cancer Research (AACR) Annual Meeting, due to its pioneering technology.

Jung-Chi Liao highlighted that Syncell continues to attract domestic and international talent, combining Taiwan's strengths in instrument development and manufacturing with international sales expertise. The company aims to establish itself as a leader in the global proteomics instrumentation market with its innovative technology.

Jung-Chi Liao also noted the recent addition of Philippe Lyko, a former senior executive at Illumina and GE, as Chief Financial Officer. Nobel Laureate William Moerner has been appointed as a scientific advisor, and biotech entrepreneur Martin Madaus, the founder of Millipore, which was acquired by Merck for $7.2 billion, has joined as a business strategic advisor. Additionally, Don Kania, a biotech instrument company executive who led FEI, acquired by Thermo Fisher for $4.2 billion, serves as a corporate advisor. These appointments have significantly strengthened the team.

In October last year, Syncell secured an investment of NT$128 million ($4 million USD) from Diamond BioFund Inc, with additional participation from Taya Venture, Harbinger Venture Capital, and Darwin Venture Management in this funding round. Combined with the $7 million USD from the Pre-A round, Syncell has raised a total of $15 million USD to date.

Syncell, a spin-off from Academia Sinica, has developed the world’s first "pickable" microscope, MicroscoopTM. The company holds unique global spatial biology technology that utilizes AI image recognition to rapidly target regions of interest within cells. Using exclusive "photo-curing reagents" and two-photon laser guidance technology, Syncell can label and isolate proteins and nucleic acids within specific cellular structures for further research.

This breakthrough technology can detect previously unknown proteins with clinical value, overcoming current limitations in spatial proteomics. It has broad applications in cellular and clinical tissue analysis, aiding in new drug development, pharmacopathology research, and drug target exploration.

Source：https://news.gbimonthly.com/tw/article/show.php?num=68069

2024-05-27
Syncell Holds Grand Opening of Headquarters Office in Taipei Bioinnovation Park

(Photo caption: From left to right: Vice President of Diamond Biofund Inc Yen Chen Huang, Project Director of Strategic Investment of Hermes-Epitek Corporation Pozo Weng, Syncell Founder and CEO Jung-Chi Liao, Institute for Biotechnology and Medicine Industry (IBMI) Vice President and Academician of Academia Sinica Dr. Pan-Chyr Yang, Director of Taya Venture Dalon Wu, Founding Partner of Darwin Venture Management Simon Fang)


Following the opening of Syncell's Boston office on April 26, the company held a grand opening ceremony for its headquarters in the Taipei Bioinnovation Park on the 27th. Distinguished guests included Dr. Pan-Chyr Yang, Academician of Academia Sinica and Vice President of the Institute for Biotechnology and Medicine Industry, who offered his congratulations. Key investors in Syncell, such as Diamond Biofund Inc., Hermes-Epitek Corporation, Taya Venture, and Darwin Venture Management, attended the ribbon-cutting ceremony.

In his speech, Dr. Pan-Chyr Yang expressed his anticipation for Syncell's future development, stating that the company's technology will bring significant changes to the biomedical field.

Jung-Chi Liao, founder and CEO of Syncell, noted that despite being established only four years ago, Syncell has already completed product development and manufacturing, successfully installing machines at customer sites in the United States. To date, Syncell’s core technology has been effectively applied in identifying previously unknown protein components related to diseases such as triple-negative breast cancer, Alzheimer's disease, amyotrophic lateral sclerosis, and fatty liver disease.

Syncell has been invited to participate in prestigious international conferences, including the 2024 Cacib-APSOT Asia Pacific Spatial Omics Technology Conference and the American Association for Cancer Research (AACR) Annual Meeting, due to its pioneering technology.

Jung-Chi Liao highlighted that Syncell continues to attract domestic and international talent, combining Taiwan's strengths in instrument development and manufacturing with international sales expertise. The company aims to establish itself as a leader in the global proteomics instrumentation market with its innovative technology.

Jung-Chi Liao also noted the recent addition of Philippe Lyko, a former senior executive at Illumina and GE, as Chief Financial Officer. Nobel Laureate William Moerner has been appointed as a scientific advisor, and biotech entrepreneur Martin Madaus, the founder of Millipore, which was acquired by Merck for $7.2 billion, has joined as a business strategic advisor. Additionally, Don Kania, a biotech instrument company executive who led FEI, acquired by Thermo Fisher for $4.2 billion, serves as a corporate advisor. These appointments have significantly strengthened the team.

In October last year, Syncell secured an investment of NT$128 million ($4 million USD) from Diamond BioFund Inc, with additional participation from Taya Venture, Harbinger Venture Capital, and Darwin Venture Management in this funding round. Combined with the $7 million USD from the Pre-A round, Syncell has raised a total of $15 million USD to date.

Syncell, a spin-off from Academia Sinica, has developed the world’s first "pickable" microscope, MicroscoopTM. The company holds unique global spatial biology technology that utilizes AI image recognition to rapidly target regions of interest within cells. Using exclusive "photo-curing reagents" and two-photon laser guidance technology, Syncell can label and isolate proteins and nucleic acids within specific cellular structures for further research.

This breakthrough technology can detect previously unknown proteins with clinical value, overcoming current limitations in spatial proteomics. It has broad applications in cellular and clinical tissue analysis, aiding in new drug development, pharmacopathology research, and drug target exploration.

Source：https://news.gbimonthly.com/tw/article/show.php?num=68069